You are viewing the site in preview mode
Skip to main content
|  | ΔBCVA (mo0 - mo9) | ΔInterval (mo0 - mo9) |
|---|
r | p-value | r | p-value |
|---|
CRT (mo0) | 0.25 | 0.0394 | 0.25 | 0.0399 |
IRF (mo0) | -0.06 | 0.6965 | 0.06 | 0.3250 |
SRF (mo0) | -0.01 | 0.9554 | 0.28 | 0.0316 |
fvPED (mo0) | 0.18 | 0.0422 | 0.17 | 0.0369 |
SHRM (mo0) | -0.04 | 0.7831 | -0.09 | 0.2642 |
Choroid (mo0) | -0.04 | 0.7582 | -0.01 | 0.2236 |
- This table displays the Spearman correlation coefficients (r) and corresponding p-values for the relationship between baseline biomarker levels and changes in best-corrected visual acuity (ΔBCVA, logMAR) and treatment interval (ΔInterval, days) from mo0 to mo9. Central retinal thickness (CRT) and fibrovascular pigment epithelium detachment (fvPED) at mo0 show a positive correlation with BCVA improvement, while CRT and subretinal fluid (SRF) levels at baseline are significantly associated with an extended treatment interval. Significant p-values are indicated in bold, suggesting that higher initial CRT, SRF, and fvPED values may predict more favorable treatment responses in refractory nAMD patients switched to Faricimab
